In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell ...
From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results